Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer

被引：0
|
作者：
Tarantino, Paolo
Lee, Do
Foldi, Julia
Soulos, Pamela R.
Gross, Cary Philip
Grinda, Thomas
Winer, Eric P.
Lin, Nancy U.
Krop, Ian E.
Tolaney, Sara M.
Lustberg, Maryam B.
Sammons, Sarah L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Yale Sch Med, New Haven, CT USA
[3] UPMC, Pittsburgh, PA USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1077
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [2] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [3] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Impact of HER2 Expression on trastuzumab deruxtecan(T-DXd) efficacy
    Chen, Wanyi
    Drago, Joshua
    Gupta, Avantika
    Liu, Bo
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2024, 84 (06)
  • [5] PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Hennig, S.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S93 - S94
  • [6] Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd)
    Lapen, Kaitlyn
    Dee, Edward Christopher Christopher
    Thom, Bridgette
    Aviki, Emeline Mariam
    Chino, Fumiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [8] Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
    Tarantino, P.
    Kim, S. E.
    Chan, N. N. N.
    Hughes, M. E.
    Smith, K.
    D'Amico, O. R.
    Kusmick, R.
    Pereslete, A. M.
    Alder, L.
    Anders, C.
    Morganti, S.
    Garrido-Castro, A. C.
    Lorusso, P.
    Lustberg, M.
    Sammons, S.
    Lin, N.
    Li, T.
    Tayob, N.
    Rimm, D.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S384 - S385
  • [9] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
  • [10] Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies
    Andrikopoulou, Angeliki
    Zagouri, Flora
    Goula, Kallirroi
    Haidopoulos, Dimitrios
    Thomakos, Nikolaos
    Svarna, Anna
    Dimopoulos, Meletios-Athanasios
    Liontos, Michalis
    BMC CANCER, 2024, 24 (01)
12345